Developing Treatments for Food Allergies Using Standardized, Pharmaceutical-Grade Food Allergens and Characterized Oral Desensitization Immunotherapy
Learn More About Aimmune
Highly selective medicines for genomically defined cancers.
Aisling congratulates the management team of Loxo on its recent acquisition by Eli Lilly.
Learn More About Loxo
Developing late-stage neuroscience compounds targeting migraine and psychiatric disorders.
Learn More About Biohaven
Novel treatments for people living with narcolepsy and other central nervous system disorders.
learn moreLearn More About Harmony Biosciences
CoolSculpting®: more science, less fat.
Aisling congratulates the management team of Zeltiq on its recent acquisition by Allergan.
Learn More About Zeltiq
Largest provider of biopharmaceutical development and commercial outsourcing services.
Learn More About QuintilesAisling Capital is a leading investment firm that invests in companies developing and commercializing important and innovative healthcare products, services and technologies.
See Our Portfolio
$1.8 billion in assets, with a track record of investing and returning capital since 2000.
learn moreLatest News
BridgeBio Pharma’s Origin Biosciences Enters Partnership With Medison To Commercialize BBP-870 In Israel For MoCD Type A
December 18, 2019
BOSTON, December 18, 2019 – BridgeBio Pharma, Inc. (Nasdaq: BBIO) subsidiary Origin Biosciences, a company focused on developing and commercializing a treatment for Molybdenum Cofactor Deficiency (MoCD) Type A, and…
READ MORE
Arcus Biosciences, in Collaboration with Genentech, Announces Two Randomized Clinical Studies to Advance AB928, a Dual Adenosine Receptor Antagonist, into Novel Combinations for Colorectal and Pancreatic Cancers
December 18, 2019
Collaboration leverages Genentech’s MORPHEUS studies to accelerate development of AB928, a potential best-in-class therapy targeting the adenosine axis to stimulate immune responses against cancer HAYWARD, Calif.--(BUSINESS WIRE)-- Arcus Biosciences, Inc.…
READ MORE
ObsEva Announces Positive Results from Uterine Fibroids Phase 3 Study (PRIMROSE 2) of Linzagolix
December 9, 2019
Phase 3 trial (PRIMROSE 2) met primary and secondary efficacy endpoints 93.9% responder rate for 200 mg with ABT (p < 0.001) 56.7% responder rate for 100 mg without ABT…
READ MORE